DNA修复基因XRCC3多态性与晚期肺腺癌患者含铂方案化疗疗效的关系  

Relationship between XRCC3 gene polymorphism and efficacy of platinum-based chemotherapy in patients with advanced lung adenocarcinoma

作　　者：张增利[1] 陈婷[1] 朱晓良[1] 余勇[1] 杜紫燕[1] 周童[1] 邢宇斐 施敏骅[1] 

机构地区：[1]苏州大学附属第二医院呼吸病科,江苏省215004

出　　处：《江苏医药》2014年第20期2392-2394,F0002,共4页Jiangsu Medical Journal

基　　金：国家自然科学基金(81272610)

摘　　要：目的探讨DNA修复基因XRCC3多态性与晚期肺腺癌患者含铂方案化疗疗效的关系。方法应用Taqman探针结合实时荧光PCR方法检测70例晚期肺腺癌患者外周血XRCC3基因多态性分布,分析XRCC3 241多态性与晚期肺腺癌患者接受一线含铂方案化疗疗效及总体生存之间的关系。结果 70例晚期肺腺癌患者总体有效率25.7%,中位生存时间为17个月。XRCC3241多态性与疗效无显著相关性。与携带XRCC3 241野生纯合基因型(Thr/Thr)患者相比,携带XRCC3 241Met突变等位基因的患者生存期延长(P<0.05)。结论 XRCC3 241Met等位基因可能与晚期肺腺癌接受含铂方案化疗后的生存时间延长有关。Objective To invsitgate the relationship between DNA repair gene（XRCC3 241） polymorphism and the effect of platinum-based chemotherapy in the patients with advanced lung adenocarcinoma. Methods The polymorphism of XRCC3 241 in peripheral blood was detected with Taqman probe combined with real time fluorescent PCR in 70 patients with advanced lung adenocarcinoma. The relationship between the polymorphism and the efficacy and overall survival time in the patients treated with first-line platinum-based chemotherapy was analyzed. Results The overall response rate was 25.7% and median survival time was 17 months. There was no significant correlation between XRCC3 241 polymorphism and efficacy. Compared with XRCC3 241 wild hom0zygous genotype （Thr/Thr）, the median survival time in the patients carrying allel Met of XRCC3 eodon 241 was prolonged（P〈0. 05）. Conclusion Allel Met of XRCC3 eodon 241 may be related to the prolongation of the overall survival time in the patients with advanced lung ad receiving platinum-based chemotherapy.

关 键 词：DNA修复基因 单核苷酸多态性 XRCC3基因 肺腺癌 

分 类 号：R734[医药卫生—肿瘤]